

University of Groningen

## Neutrophil-endothelial interaction in ANCA associated vasculitis

Hu, Nan

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2011

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Hu, N. (2011). *Neutrophil-endothelial interaction in ANCA associated vasculitis*. s.n.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

**Decreased CXCR<sub>1</sub> and CXCR<sub>2</sub> expression on neutrophils in ANCA-associated vasculitides potentially increases neutrophil adhesion and impaires migration**

Nan Hu  
Johanna Westra  
Wayel H Abdulahad  
Bram Rutgers  
Simon C Satchell  
Berber Doornbos-Van der Meer  
Peter W Mathieson  
Minke G Huitema  
Peter Heeringa  
Coen A Stegeman  
Cees GM Kallenberg

*Submitted for publication*

**Abstract**

**Objectives:** In anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV), persistent inflammation within the vessel wall suggests perturbed neutrophil trafficking leading to accumulation of activated neutrophils in the microvascular compartment. CXCR<sub>1</sub> and CXCR<sub>2</sub>, being major chemokine receptors on neutrophils, are largely responsible for neutrophil recruitment. We speculate that down-regulated expression of CXCR<sub>1/2</sub> retains neutrophils within the vessel wall and, consequently, leads to vessel damage.

**Methods:** Membrane expression of CXCR<sub>1/2</sub> on neutrophils was assessed by flow cytometry. Serum levels of IL-8, TNF- $\alpha$ , angiopoietin 1 and angiopoietin 2 from quiescent and active AAV patients and healthy controls (HC) were quantified by ELISA. Adhesion and transendothelial migration of isolated neutrophils was analyzed using adhesion assays and Transwell systems, respectively.

**Results:** Expression of CXCR<sub>1</sub> and CXCR<sub>2</sub> on neutrophils was significantly decreased in AAV patients compared to HC. Levels of IL-8, which dose-dependently down-regulated CXCR<sub>1</sub> and CXCR<sub>2</sub> expression on neutrophils *in vitro*, were significantly increased in the serum of patients with active AAV and correlated negatively with CXCR<sub>1</sub>/CXCR<sub>2</sub> expression on neutrophils, even in quiescent patients. Blocking CXCR<sub>1</sub> and CXCR<sub>2</sub> with repertaxin increased neutrophil adhesion and inhibited migration through a glomerular endothelial cell layer.

**Conclusion:** Expression of CXCR<sub>1</sub> and CXCR<sub>2</sub> is decreased in AAV, potentially induced by circulating IL-8. Down-regulation of these chemokine receptors could increase neutrophil adhesion and impair its migration through the glomerular endothelium, resulting in neutrophil accumulation and, consequently, persistent inflammation within the vessel wall.

## Introduction

AAV comprises granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and Churg Strauss syndrome (CSS), which share a spectrum of clinical manifestations reflecting necrotizing damage to small- and medium-sized vessels.<sup>1,2</sup> A role for neutrophils as effector cells in AAV is supported by a large body of evidence from *in vitro* and *in vivo* studies. After being primed by proinflammatory cytokines such as TNF- $\alpha$ , neutrophils can be activated by ANCA and release oxygen radicals and proteolytic enzymes, which have been shown to lyse endothelial cells in *in vitro* co-cultures.<sup>3,4</sup> *In vivo*, neutrophil accumulation in glomeruli has been observed in the early phase of crescentic glomerulonephritis and neutrophil depletion could completely prevent disease development in experimental models.<sup>5</sup>

Migration of neutrophils is largely regulated by the concentration gradient of CXC-chemokines which contain a glutamic acid-leucine-arginine (ELR<sup>+</sup>) motif and are the most powerful chemoattractants for neutrophils. Interleukin 8 (IL-8) is the most potent member of the CXC family with high affinity for both of its receptors, CXCR<sub>1</sub> and CXCR<sub>2</sub>, which are co-expressed on the membrane of neutrophils. Thus, binding of IL-8 to CXCR<sub>1/2</sub> is a major element in neutrophil recruitment.<sup>6</sup>

Neutrophils function in immune surveillance. Their activation, in terms of degranulation and oxidative burst, arms neutrophils with microbicidal activity, which normally appears only after they have migrated from the circulation and reach inflamed tissues.<sup>7</sup> However, in the pathology of AAV, necrotizing damage within the vessel wall suggests that ANCA-mediated neutrophil activation is already triggered during neutrophil recruitment. This may be caused by impaired neutrophil trafficking retaining activated neutrophils within the microvascular compartment.

Although consensus is still lacking whether ANCA bind to neutrophils in suspension, it has been well demonstrated that membrane bound-PR<sub>3</sub> on neutrophils is significantly upregulated during neutrophil adhesion, and full neutrophil activation not only requires ANCA-antigen cross-linking but also adherence of neutrophils.<sup>8-11</sup> Here, we hypothesize that IL-8-CXCR<sub>1</sub>/CXCR<sub>2</sub>-mediated neutrophil recruitment is hampered in AAV, which leads to firm adhesion of neutrophils to the endothelium without further transmigration. Retained neutrophils within the microvascular compartment may be activated by ANCA, which will result in persistent inflammation of the vessel wall. To test this hypothesis, we investigated expression profiles of CXCR<sub>1</sub> and CXCR<sub>2</sub> on

neutrophils in patients with AAV, related expression to levels of chemoattractants, and analyzed effects on transmigration.

## **Materials and Methods**

### **Patients and healthy controls**

For measurement of CXCR<sub>1</sub> and CXCR<sub>2</sub> expression, 37 patients with quiescent AAV and 5 AAV patients with active disease were recruited from our out-patient clinic. Thirty healthy donors recruited from laboratory personnel were included as a normal control population. Demographic characteristics of patients and controls are summarized in Table 1.

A diagnosis of granulomatosis with polyangiitis (GPA), Churg Strauss syndrome (CSS) or microscopic polyangiitis (MPA) was based on the Chapel Hill definitions.<sup>12</sup> ANCA specificity for PR<sub>3</sub> or MPO was determined by capture ELISA. Patients in remission were receiving none or minimal treatment. Treatment of active patients is listed in Table 1. Disease severity was quantified using the Birmingham Vasculitis Activity Score (BVAS).

Sera from AAV patients and healthy volunteers were collected for cytokine profiling. For patients in remission, samples were drawn on the same day for CXCR<sub>1/2</sub> measurement and cytokine testing. For patients who were in remission but had suffered from active disease before (n=18), serum samples from active disease were retrieved from a stored serum bank. All sera were stored at -80°C before testing.

All subjects gave their informed consent and the study was approved by the hospital medical ethical committee.

### **Antibodies used for flow cytometry**

Peridin chlorophyll protein (PerCP)/Cy5.5-conjugated anti-CD14 (HCD14; Biolegend, San Diego, CA) was used to discriminate neutrophils from monocytes in whole blood staining. Phycoerythrin (PE)-conjugated anti-CD181 (CXCR<sub>1</sub>, 5A12; BD Bioscience, Alphen aan de Rijn, The Netherlands), allophycocyanin (APC)-conjugated anti-CD182 (CXCR<sub>2</sub>, 6C6; BD bioscience, Alphen aan de Rijn, The Netherlands) and fluorescein isothiocyanate (FITC)-conjugated anti-CD177 (NB1, MEM166; abCAM, Cambridge, UK) were used to detect membrane expression of CXCR<sub>1</sub>, CXCR<sub>2</sub> and CD177, respectively. Irrelevant antibodies of the same isotype were used as negative controls.

### **Cell culture**

Human conditionally immortalized glomerular endothelial cells (CiGenC)<sup>13</sup> were cultured in endothelial growth medium 2-microvascular (EGM2-MV; Cambrex-Lonza, Breda, The Netherlands) containing 5% fetal calf serum and growth factors, without vascular endothelial growth factor (VEGF), as supplement. CiGenC up to passage 40 were propagated at 33°C to keep cells in a proliferative

**Table 1.** Characteristics of patients and controls\*

Characteristics	n (%) or mean (range)			
	HC (n=30)	AAV		
		Remission (n=37)	Active <sup>†</sup> (n=5)	Active <sup>‡</sup> (n=18)
Male	17 (57)	25 (68)	3 (60)	14 (78)
Age (years)	45 (28~64)	57 (26~84)	58 (47~68)	58 (32~81)
<b>Diagnosis</b>				
	GPA	26	4	13
	MPA	9	1	5
	NCGN	2	0	0
<b>ANCA-specificity</b>				
	PR3	24 (65)	4 (80)	13 (72)
	MPO	13 (35)	1 (20)	5 (28)
<b>Organ involvement</b>				
	ENT	0	4 (80)	5 (28)
	Eye	0	1 (20)	4 (22)
	Lung	0	4 (80)	8 (44)
	Kidney	0	2 (40)	13 (72)
	Skin	0	1 (20)	0
	Nervous system	0	1 (20)	2 (11)
BVAS, median (range)		0	14.8 (6~26)	17.5 (6~33)
<b>Treatment</b>				
	MMF	0	1 (20)	3 (17)
	CYC	0	4 (80)	11 (61)
	Prednisolon	0	4 (80)	16 (89)

\*, HC= healthy control; AAV= ANCA-associated vasculitides; GPA= granulomatosis with polyangiitis; MPA= microscopic polyangiitis; NCGN= necrotizing crescentic glomerulonephritis; PR3= proteinase 3; MPO= myeloperoxidase; ENT= ear, nose and throat; BVAS= Birmingham Vasculitis Activity Score; MMF= mycophenolate mophetil; CYC= cyclophosphamide. <sup>†</sup>, Active patients included in CXCR<sub>1</sub> and CXCR<sub>2</sub> measurement by flow cytometry. <sup>‡</sup>, Active patients included in cytokine profiling by ELISA.

state. Experiments were carried out on cells that had grown into a confluent monolayer and had been incubated for 5 days at 37°C in order to acquire a non-proliferative/quiescent phenotype.

### **Neutrophil isolation and stimulation**

Neutrophils were isolated from peripheral blood according to routine procedures as described previously.<sup>14</sup> Briefly, heparinized venous blood was centrifuged on Lymphoprep (Axis-Shield, Oslo, Norway). Contaminating erythrocytes were lysed with ice-cold ammonium chloride buffer. Afterwards, cells were washed with cold Hanks' balanced salt solution (HBSS) without  $\text{Ca}^{2+}/\text{Mg}^{2+}$  (HBSS<sup>-</sup>) and resuspended in HBSS with  $\text{Ca}^{2+}/\text{Mg}^{2+}$  (HBSS<sup>+/+</sup>; GIBCO/Life Technologies, Breda, The Netherlands) to obtain  $10^7$  cells/ml.

Where indicated, cells were incubated with serial doses of interleukin-8 (IL-8; R&D Systems, Minneapolis, MN USA), angiopoietin-1 (ANGPT-1; R&D Systems, Minneapolis, MN USA), angiopoietin-2 (ANGPT-2; R&D Systems, Minneapolis, MN USA), recombinant human tumor necrosis factor- $\alpha$  (rhTNF- $\alpha$ ; R&D Systems, Minneapolis, MN USA) or repertaxin (Sigma-Aldrich, USA) at 37°C for 30 min. Non-stimulated cells were incubated with control medium under the same condition.

### **Membrane staining of neutrophils for flow cytometry**

Membrane expression of CXCR1, CXCR2 and CD177 on neutrophils was assessed by flow cytometry. According to the manufacturer's instructions, 100  $\mu\text{l}$  of whole blood from patients and controls or  $10^6$  of purified neutrophils after in vitro stimulation were incubated with antibodies at room temperature, in the dark, for 15 min, followed by fixation and lysing of erythrocytes with 20x volume of FACS lysing solution (BD Bioscience, San Jose, CA). Fluorescence intensity was measured by FACS Calibur (Becton Dickinson Immunocytometry Systems, Mountain View, CA, USA) and calibrated using CellQuest<sup>TM</sup> software (Becton Dickinson). Results were analyzed using Win-List software package (Verity Software House, Topsham, ME). Mean fluorescence intensity (MFI) of  $5 \cdot 10^4$  counted cells was measured in each sample. Neutrophils were gated as forward scatter<sup>high</sup> (FSC<sup>high</sup>)-side scatter<sup>high</sup> (SSC<sup>high</sup>)-CD14<sup>low</sup> cells. Expression levels were presented as MFI corrected for nonspecific binding of isotype control antibodies on neutrophils from the same donor.

### **MPO activity assay**

Numbers of adherent or migrated neutrophils in adhesion or migration assay were quantified by myeloperoxidase (MPO) activity assay.<sup>15</sup> Briefly, cells were lysed with 0.5% Triton-X-100 at 4°C for 20 min and acidified by adding 1M citrate buffer (pH=4.2, 50 µl/ 1 ml of cell lysate) just prior to the reaction. Aliquots (75 µl) from each sample were transferred into wells of a flat-bottomed 96-well plate. 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS) at a concentration of 0.05% in 100 mM citrate with 0.03% H<sub>2</sub>O<sub>2</sub> was loaded in an equal volume as substrate for MPO. After the reaction, OD<sub>405</sub> was measured using an ELISA plate reader. Numbers of neutrophils in each well was determined as based on standards generated from known concentrations of neutrophils from the same isolation.

### Neutrophil adhesion

Neutrophil adhesion to endothelial monolayers was quantified by adhesion assay as described previously with modifications.<sup>16</sup> CiGenCs were seeded in 24-well plates and allowed to proliferate to confluence. Cell monolayers were carefully washed with HBSS<sup>+/+</sup> and stimulated with 10 ng/ml TNF-α at 37°C for 4 hrs. Cells were then washed three times before  $0.5 \times 10^6$  neutrophils were loaded. Where indicated, neutrophils were pretreated with serial doses of IL-8, TNF-α or repertaxin which is a noncompetitive allosteric inhibitor of CXCR<sub>1</sub> and CXCR<sub>2</sub>.<sup>17</sup> After incubation of endothelial cells with neutrophils at 37°C for 30 min, loosely adherent or non-adherent neutrophils were washed off with HBSS<sup>-/-</sup> and the endothelial monolayers plus adherent neutrophils were lysed in 0.5% Triton-X-100. All experiments were run in duplicate. The numbers of neutrophils were quantified, as described above, by MPO activity assay.

### Neutrophil migration

Transwell inserts (Coring, NY, USA), with 3.0 µm pores in 12-well plates, were precoated with CiGenCs. Confluence of the endothelial monolayers was determined by continued monitoring trans-endothelial electrical resistance (TEER)<sup>13</sup> which plateaued at 20-25 Ω on the 5<sup>th</sup> day after seeding. Histological staining of the membrane showed that the formation of monolayers on inserts required  $6 \times 10^4$  cells and 5 days of culture. Therefore, all the Transwell inserts were coated with CiGenCs following this standard procedure. Isolated neutrophils from healthy donors were preincubated with repertaxin, IL-8 or TNF-α, and  $1.10^6$  cells were loaded in the upper chamber. 10ng/ml of IL-8, which showed optimal efficiency as chemoattractant in titration in preliminary experiments (data not shown), was placed in the lower chamber. Wells without



IL-8 in the lower chamber or neutrophils without any treatment in the upper chamber were included as controls. All experiments were run in duplicates. After coincubation of neutrophils with the inserts at 37°C for 2 hrs, the plates with inserts within the wells were centrifuged for 5 min at 50g and 4°C to dislodge adherent neutrophils on the lower surface of the inserts. The cells in the lower chamber were collected and quantified by MPO activity assay.

### **Serum levels of IL-8, TNF- $\alpha$ , angiopoietin-1 (ANGPT-1) and angiopoietin-2 (ANGPT-2)**

Sera collected from AAV patients in remission (n=37), patients with active disease (n=18) and healthy blood donors (n=30) were used for measurement of IL-8, TNF- $\alpha$ , ANGPT-1 and ANGPT-2. IL-8 and TNF- $\alpha$  levels were measured by ELISA (R&D Systems, Minneapolis, MN) as described previously.<sup>18</sup> After sample incubation and binding of the biotinylated detecting antibodies, color reaction was performed with streptavidin-poly-HRP (Sanquin, Amsterdam, the Netherlands) and tetramethyl-benzidin (TMB, Roth, Karlsruhe, Germany). Levels of angiopoietin-1 and angiopoietin-2 in sera were measured using ELISA kits (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.

Normal levels of these cytokines in serum were defined as the mean $\pm$ 2SD of healthy controls.

### **Statistical analysis**


Results of CXCR1 and CXCR2 expression are presented as medians. Serum levels of IL-8, TNF- $\alpha$ , ANGPT-1 and ANGPT-2 and membrane expression of adhesion molecules are presented as means. Data were analyzed by Mann-Whitney test and Spearman's rank correlation test using GraphPad Prism 4.03 (GraphPad Software, San Diego, CA). P values less than 0.05 were considered significant.

## **Results**

### **Expression of CXCR1 and CXCR2 on the neutrophil membrane is decreased in AAV**

We first evaluated expression levels of CXCR1 and CXCR2 on neutrophils in AAV patients (remission, n=37; active, n=5) in comparison with healthy blood donors (n=30). Both receptors were highly expressed on the membrane of neutrophils. Neutrophils from patients in remission (median 1153, range 640~1986) showed lower, although not statistically significant, expression of CXCR1 than those from HC (1163, 790~1790, p=0.3), while neutrophil CXCR1 levels were significantly decreased in patients with active disease (533, 416~1071) compared to either HC

( $p=0.003$ ) or patients in remission ( $p=0.0023$ ) (Figure 1A). CXCR2 expression was significantly down-regulated in AAV patients in remission (453, 201~817) compared to HC (589, 290~941,  $p=0.0004$ ) and further decreased in active patients (323, 242~564) as compared to HC ( $p=0.0086$ ) (Figure 1B). A significant correlation was observed between the expression of CXCR1 and CXCR2 on neutrophils of AAV patients, regardless of disease activity (Figure 1C, spearman  $r=0.87$ ,  $p<0.0001$ ).




**Figure 1. Down-regulated expression of CXCR1 and CXCR2 on neutrophils in AAV.**

Levels of CXCR1 (A) and CXCR2 (B) expression on the membrane of neutrophils were measured by flowcytometry and compared between AAV patients in remission ( $n=37$ ), AAV patients with active disease ( $n=5$ ) and healthy controls (HC,  $n=30$ ). Expression levels are presented as MFI corrected for nonspecific binding of isotype control antibodies on neutrophils. Horizontal lines represent medians. \*,  $p<0.05$ ; \*\*,  $p<0.01$ ; \*\*\*,  $p<0.001$ . Correlation between CXCR1 and CXCR2 expression (C) on neutrophils was analyzed in patients in remission and with active disease ( $n=42$ , Spearman  $r=0.87$ ,  $p<0.0001$ ). Dotted line represents the best-fit correlation between CXCR1 and CXCR2 expression.


## IL-8 and TNF- $\alpha$ down-regulate CXCR<sub>1</sub>/CXCR<sub>2</sub> from the neutrophil membrane

IL-8 and TNF- $\alpha$  are proinflammatory cytokines reported to be elevated in the serum of AAV patients.<sup>19-21</sup> Serum levels of ANGPT-2 have also recently been reported to be increased in AAV and to correlate with disease activity.<sup>22</sup> IL-8 is also produced by endothelial cells stimulated with ANGPT-1.<sup>23</sup> Therefore, we tested the influences of these cytokines on CXCR<sub>1</sub> and CXCR<sub>2</sub> expression. As a result, both IL-8 and TNF- $\alpha$  down-regulated CXCR<sub>1</sub> and CXCR<sub>2</sub> expression on isolated neutrophils in a dose-dependent manner. IL-8, at a concentration of 5ng/ml, reduced CXCR<sub>2</sub> levels to 61% compared to control incubation with normal medium, while IL-8 down-regulated membrane expression of CXCR<sub>1</sub> to 71% at 20ng/ml (Figure 2A). TNF- $\alpha$  significantly reduced CXCR<sub>1</sub>/CXCR<sub>2</sub> expression already at a dose of 1 ng/ml (Figure 2B). When tested in parallel,



**Figure 2. Down-regulation of CXCR<sub>1</sub> and CXCR<sub>2</sub> on neutrophils by IL-8 and TNF $\alpha$ .**

Isolated neutrophils were pre-incubated with serial doses of IL-8 (A), TNF $\alpha$  (B), ANGPT-1 (C) or ANGPT-2 (D). Membrane expression of CXCR<sub>1</sub> (●) and CXCR<sub>2</sub> (◆) was measured by flow cytometry. Expression of CD177 (○) was measured in parallel as control for stimulation. Results are presented as percentages compared to control incubation with normal medium (ctrl). CXCR<sub>1</sub> and CXCR<sub>2</sub> are equally down-regulated by TNF $\alpha$  (overlapping graphs in panel B). Results are the mean ( $\pm$ SD) of three experiments, \*,  $p < 0.05$ ; \*\*,  $p < 0.01$  (CXCR<sub>1</sub> and CD177). #,  $p < 0.01$  (CXCR<sub>2</sub>).



**Figure 3. Levels of IL-8, ANGPT-1 and ANGPT-2 in sera from patients with AAV.**


Levels of IL-8 (A), ANGPT-1 (B) and ANGPT-2 (C) in sera of AAV patients in remission (n=37) and active disease (n=18) were measured by ELISA and compared to HC (n=30). Results are presented as the concentration of each cytokine in serum. Bars denote medians, \*,  $p < 0.05$ ; \*\*\*,  $p < 0.001$ .

CD177 (NB1) expression was slightly increased by IL-8 and significantly up-regulated by TNF- $\alpha$ , as reported in earlier studies.<sup>14,24</sup> ANGPT-1 and ANGPT-2 did not affect CXCR1/CXCR2 or CD177 expression on isolated neutrophils (Figure 2C and 2D).

### Serum levels of IL-8, TNF- $\alpha$ , ANGPT-1 and ANGPT-2 in AAV

Levels of the cytokines mentioned above, which may have direct or indirect effects on CXCR1/CXCR2 expression, were evaluated in our patient cohort in comparison with HC.

Defining the normal range as mean $\pm$ 2SD of the IL-8 concentration in 30 healthy controls, 5 out of 37 (14%) patients in remission and 10 out of 18 (56%) active patients showed increased IL-8 levels. Levels of IL-8 were not significantly different between patients with quiescent AAV (median 2.81 pg/ml, range 0.0–19.64 pg/ml) and healthy controls (2.30 pg/ml, 0–15.43 pg/ml). However, a negative correlation was present between CXCR1/CXCR2 expression on neutrophils and levels of IL-8 in patients in remission (Figure 4). A negative correlation was not observed between IL-8 and CXCR1/2 in active AAV, probably due to the small sample size. Nevertheless, in concert with further decreased



**Figure 4. CXCR<sub>1</sub>/CXCR<sub>2</sub> expression correlates with IL-8 levels in quiescent AAV.**

Expression of CXCR<sub>1</sub>, CXCR<sub>2</sub> and levels of IL-8 were measured in parallel in patients in remission ( $n=37$ ). Membrane expression of CXCR<sub>1</sub> and CXCR<sub>2</sub> is presented as MFI corrected for nonspecific binding of isotype control antibodies on neutrophils. IL-8 levels are presented as concentration in serum. A. Correlation between CXCR<sub>1</sub> expression on neutrophils and serum levels of IL-8 (Spearman  $r = -0.34$ ,  $p = 0.04$ ). B. Correlation between CXCR<sub>2</sub> expression on neutrophils and serum levels of IL-8 (Spearman  $r = -0.41$ ,  $p = 0.01$ ). Dotted lines represent the best-fit correlation between expression of CXCR<sub>1/2</sub> and IL-8 levels.

CXCR<sub>1/2</sub> expression, IL-8 levels increased remarkably during active disease (8.67 pg/ml, 3.96~ 51.55 pg/ml), and were significantly higher than levels in HC and patients in remission (Figure 3A). These data suggest that IL-8 in the circulation, also during remission, may be responsible for decreased expression of CXCR<sub>1</sub>/CXCR<sub>2</sub> on the membrane of neutrophils in AAV.

As for levels of ANGPT-1, no significant difference was observed between HC and patients in remission. The median level of ANGPT-1 in active patients was lower than in HC (Figure 3B). Levels of ANGPT-2 were not increased in patients in remission nor in patients with active disease (Figure 3C). TNF- $\alpha$  was not detectable in sera of either HC or patient groups.


### Neutrophil recruitment after CXCR<sub>1</sub>/CXCR<sub>2</sub> blockade

To further clarify possible consequences of CXCR<sub>1</sub> and CXCR<sub>2</sub> down-regulation on neutrophils, we investigated neutrophil adhesion and transmigration through a glomerular endothelial monolayer. Neutrophils were pretreated with repertaxin, mimicking decreased efficiency of IL-8 receptors, or stimulated with IL-8/TNF- $\alpha$ , both of which lead to decline of CXCR<sub>1</sub> and CXCR<sub>2</sub> expression.

Glomerular endothelial cell layers were stimulated with 10 ng/ml of TNF- $\alpha$  for 4 hours prior to the adhesion or migration assay to mimic activated glomerular endothelial cells as occurs in AAV. Preincubation with repertaxin inhibited neutrophil migration in a dose-dependent way. 100nM of repertaxin reduced migration to 76%, significantly lower than control incubated neutrophils. IL-8 preincubation reduced the number of migrated neutrophils to 39%. Although

incubation with TNF- $\alpha$  resulted in a significantly reduced expression of CXCR<sub>1</sub>/CXCR<sub>2</sub> on the membrane of neutrophils, migration was not significantly influenced, and numbers of migrated neutrophils were comparable with control incubation (Figure 5B).

Neutrophils preincubated with 2 ng/ml TNF- $\alpha$  showed enhanced adhesion to glomerular endothelium compared to control incubation. IL-8 (up to 20 ng/ml), however, did not show a remarkable effect on neutrophil adhesion. Blocking



**Figure 5. CXCR<sub>1</sub>/CXCR<sub>2</sub> blockade enhances neutrophil adhesion and inhibits neutrophil transmigration through an endothelial cell monolayer.**

Isolated neutrophils were pre-incubated with serial doses of repertaxin, IL-8 (10 ng/ml) or TNF $\alpha$  (2 ng/ml) before being loaded onto a glomerular endothelial monolayer or a transwell insert. After co-incubation of pretreated neutrophils with glomerular endothelial cells for 30 min for the adhesion assay (A, n=5) or with transwell inserts coated with endothelial cells for 2 hrs (B, n=6), the number of adherent or migrated neutrophils were quantified by MPO activity assay. Results are presented as the percentages of adherent or migrated neutrophils after stimulation compared to control incubation. \*, p < 0.05

CXCR<sub>1</sub> and CXCR<sub>2</sub> with repertaxin also increased the number of adherent neutrophils dose-dependently, from 135% with 10 nM of repertaxin up till more than 300% at 0.5  $\mu$ M as compared to cells without stimulation (Figure 5A).

## Discussion

This is the first study, to our knowledge, reporting decreased expression of CXCR<sub>1</sub> and CXCR<sub>2</sub> on neutrophils in AAV, potentially induced by IL-8. Functional deficiency of CXCR<sub>1</sub>/CXCR<sub>2</sub>, induced by specific inhibition of these receptors with repertaxin, increased neutrophil adhesion and impaired migration through a glomerular endothelium monolayer. Down-regulation of CXCR<sub>1</sub> and CXCR<sub>2</sub> may retain activated neutrophils within the vessel wall, allowing interaction with circulating ANCA, so leading to vascular damage in situ. These findings highlight a chemokine-receptor-based mechanism of inflammation confined within the vessel wall and would further explain the role of neutrophils in the pathogenesis of AAV.

CXCR<sub>1</sub> and CXCR<sub>2</sub> are not stably expressed on the neutrophil membrane. During chemotaxis, ligand-mediated internalization and recycling of these chemokine receptors is proposed as a self-limiting mechanism allowing neutrophils, by desensitization to their ligands, to retain in situ, once they reach their targets.<sup>25</sup> However, this physiological process is probably abused in AAV, and down-regulated CXCR<sub>1</sub>/CXCR<sub>2</sub> expression may desensitize circulating neutrophils to chemotactic signals before they migrate into the tissue resulting in accumulation of neutrophils within the vessel wall.

Our *in vitro* experiments confirmed this hypothesis by showing significantly increased adhesion and decreased migration of neutrophils through glomerular endothelium after CXCR<sub>1</sub> and CXCR<sub>2</sub> blockade. This is in line with our previous observation that, in a model of MPO-ANCA-associated vasculitis, repertaxin treated mice were not protected from haematuria, albuminuria or glomerular crescent formation. Instead, we observed a larger number of neutrophils accumulating in glomeruli in comparison to untreated mice.<sup>26</sup> Besides, CXCR<sub>1</sub>/CXCR<sub>2</sub>-knockout mice showed deficiency in neutrophil migration and bacterial clearance in a urinary tract infection model, and decline in CXCR<sub>1</sub>/CXCR<sub>2</sub> expression may worsen outcome of infections due to impaired neutrophil recruitment.<sup>27-31</sup>

Notably, down-regulation of CXCR<sub>1</sub> and CXCR<sub>2</sub> from the neutrophil surface may not be specific for AAV. As IL-8 is a potential inducer of decreased CXCR<sub>1/2</sub> expression, increased levels of circulating IL-8 in other clinical conditions may also result in a similar decline of CXCR<sub>1/2</sub> expression. In addition, our results may reflect a state of neutrophil activation mediated by IL-8 or other proinflammatory cytokines, such as TNF $\alpha$ , as has been described in AAV by Muller Kobold et al. previously.<sup>32</sup> In the presence of ANCA, however, pre-activated neutrophils lacking CXCR<sub>1/2</sub> expression can be confined in the microvasculature and fully activated by ANCA.

The role of CXCR<sub>1</sub> and CXCR<sub>2</sub> in neutrophil adhesion has not been clearly delineated. Blocking of IL-8-receptors showed an inhibitory effect on IL-8-induced neutrophil adhesion in an early study.<sup>33</sup> The underlying mechanisms are not fully elucidated so far. A recent study conducted by Cohen-Hillel et al. showed that migratory desensitization triggers over-activation of focal adhesion kinase (FAK), which leads to increased neutrophil adhesion.<sup>34</sup> The latter mechanism is likely operative in AAV, where neutrophils are migratory desensitized under continuous exposure to low-dose IL-8.<sup>20</sup> Besides, in our experiments, neutrophils pretreated with repertaxin did show significantly increased adhesion on an activated CiGenC monolayer. As endothelial cells might

also be actively involved in neutrophil-endothelial interaction during inflammation, this adhesive effect may also depend on endothelial phenotypes and microenvironment, explaining why Coelho et al. observed short-term suppression of neutrophil adhesion to synovial endothelium after repertaxin treatment in a mouse model of arthritis.<sup>35</sup> Glomerular endothelial cells (ECs) have unique features and differ from synovial ECs in many ways, such as expression profile of adhesion molecules.<sup>36</sup> Besides, neutrophil recruitment in an in vitro model of rheumatoid arthritis only occurs in co-cultures of ECs with synovial fibroblasts but not with control tissues,<sup>37</sup> suggesting that immune regulators in the microenvironment also play an important role in this process.

Since CXCR<sub>1</sub> and CXCR<sub>2</sub> are internalized upon ligation and IL-8 has been shown to be significantly elevated in AAV patients,<sup>20</sup> we speculate that IL-8 is one of the factors inducing decreased expression of these receptors. Indeed, we found that CXCR<sub>1</sub> and CXCR<sub>2</sub> expression was remarkably lower in patients with active AAV than in HC. Decreased expression was accompanied by significantly elevated serum levels of IL-8 in active AAV. Moreover, a negative correlation was observed between CXCR<sub>1</sub>/CXCR<sub>2</sub> expression and serum IL-8 levels in patients with quiescent disease. As an indirect evidence of this relationship, a negative effect of serum IL-8 on neutrophil recruitment has been demonstrated in earlier studies, which was supposed to be caused by down-regulation of IL-8 receptors.<sup>38,39</sup> Cockwell et al. proposed a similar scenario in AAV by showing that ANCA-activated neutrophils produce IL-8 and that neutrophils accumulate locally in the glomerular capillary loops but poorly penetrate into IL-8 enriched tissues as observed in renal biopsies of AAV patients.<sup>40</sup> From the data of the present study, a relationship is suggested between circulating IL-8 levels, decrease in CXCR<sub>1</sub>/CXCR<sub>2</sub> expression and neutrophil accumulation in the microvasculature in AAV.

Circulating IL-8 can be produced by ANCA-activated neutrophils and endothelial cells stimulated by IL-1, TNF- $\alpha$  or PR<sub>3</sub>-ANCA.<sup>40-42</sup> Although circulating IL-8 levels were not significantly elevated in patients during remission, it should be noted that a low-level of immune activation is present during quiescent disease as well, including minor increase in IL-8 levels.<sup>43</sup>

CXCR<sub>1</sub> and CXCR<sub>2</sub> expression can also be regulated through enzymatic cleavage via metalloproteinases,<sup>44</sup> by other immunomodulators such as TNF- $\alpha$  which have been detected at inflammatory sites in AAV and prime neutrophils for ANCA-induced activation.<sup>20,45-47</sup> Technical limitations to measure TNF $\alpha$  in serum could have hampered to reveal the relationship between TNF $\alpha$  levels and CXCR<sub>1/2</sub> expression. As shown in the current study, TNF- $\alpha$ , up till a concentration of 20



ng/ml, was more efficient than IL-8 in down-regulating CXCR<sub>1</sub>/CXCR<sub>2</sub> in vitro. Therefore, although TNF- $\alpha$  could not be detected in sera, there is still the possibility that increased levels of TNF- $\alpha$ , especially during active disease, lead to a decrease in CXCR<sub>1</sub> and CXCR<sub>2</sub> expression.

It needs to be mentioned that the number of patients with active AAV included in the current study was relatively small, so not allowing firm conclusions as to the correlation between neutrophil CXCR<sub>1</sub> and CXCR<sub>2</sub> expression and disease activity. Such a correlation is, however, suggested by the further decrease of CXCR<sub>1</sub> and CXCR<sub>2</sub> expression that we observed during active disease. Furthermore, immunohistochemical studies are needed to show lack of CXCR<sub>1</sub> and CXCR<sub>2</sub> expression on neutrophils recruited to the vascular wall in AAV. Such data could further strengthen the role of CXCR<sub>1</sub> and CXCR<sub>2</sub> down-regulation in AAV.

In conclusion, expression of CXCR<sub>1</sub> and CXCR<sub>2</sub> on neutrophils is down-regulated in AAV patients, potentially induced by circulating IL-8. Decreased expression of these chemokine receptors may enhance neutrophil adhesion and impede neutrophil migration through activated glomerular endothelium, which may account for neutrophil accumulation and persistent ANCA-induced inflammation in the vessel wall.

## References

1. Jennette JC, Falk RJ. Small-vessel vasculitis. *N Engl J Med* 1997;337:1512-23.
2. Callenberg CG, Heeringa P, *et al.* Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides. *Nat Clin Pract Rheumatol* 2006;2:661-70.
3. Falk RJ, Terrell RS, *et al.* Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. *Proc Natl Acad Sci U S A* 1990;87:4115-9.
4. Savage CO, Pottinger BE, *et al.* Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. *Am J Pathol* 1992;141:335-42.
5. Xiao H, Heeringa P, *et al.* The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. *Am J Pathol* 2005;167:39-45.
6. Murphy PM. Neutrophil receptors for interleukin-8 and related CXC chemokines. *Semin Hematol* 1997;34:311-8.
7. Pham CT. Neutrophil serine proteases: specific regulators of inflammation. *Nat Rev Immunol* 2006;6:541-50.
8. Abdel-Salam B, Iking-Konert C, *et al.* Autoantibodies to neutrophil cytoplasmic antigens (ANCA) do not bind to polymorphonuclear neutrophils in blood. *Kidney Int* 2004;66:1009-17.
9. Brachemi S, Mambole A, *et al.* Increased membrane expression of proteinase 3 during neutrophil adhesion in the presence of anti proteinase 3 antibodies. *J Am Soc Nephrol* 2007;18:2330-9.
10. Reumaux D, Vossebeld PJ, *et al.* Effect of tumor necrosis factor-induced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. *Blood* 1995;86:3189-95.
11. Van Rossum AP, Van Der Geld YM, *et al.* Human anti-neutrophil cytoplasm autoantibodies to proteinase 3 (PR3-ANCA) bind to neutrophils. *Kidney Int* 2005;68:537-41.

12. Jennette JC, Falk RJ, *et al.* Nomenclature of systemic vasculitides. Proposal of an international consensus conference. *Arthritis Rheum* 1994;37:187-92.
13. Satchell SC, Tasman CH, *et al.* Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF. *Kidney Int* 2006;69:1633-40.
14. Hu N, Westra J, *et al.* Coexpression of CD177 and membrane proteinase 3 on neutrophils in antineutrophil cytoplasmic autoantibody-associated systemic vasculitis: anti-proteinase 3-mediated neutrophil activation is independent of the role of CD177-expressing neutrophils. *Arthritis Rheum* 2009;60:1548-57.
15. Louis NA, Campbell E, *et al.* Model systems to investigate neutrophil adhesion and chemotaxis. In: Quinn MT, Deleo FR, Bokoch GM, eds. *Neutrophil methods and protocols*. Totowa: Humana Press; 2007:257-72.
16. Zouki C, Beauchamp M, *et al.* Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. *J Clin Invest* 1997;100:522-9.
17. Bertini R, Allegretti M, *et al.* Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. *Proc Natl Acad Sci U S A* 2004;101:11791-6.
18. Westra J, Brouwer E, *et al.* Expression and regulation of HIF-1 $\alpha$  in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor. *BMC Musculoskelet Disord* 2010;11:61.
19. Jonasdottir O, Petersen J, *et al.* Tumour necrosis factor- $\alpha$  (TNF), lymphotoxin and TNF receptor levels in serum from patients with Wegener's granulomatosis. *APMIS* 2001;109:781-6.
20. Ohlsson S, Wieslander J, *et al.* Circulating cytokine profile in anti-neutrophilic cytoplasmic autoantibody-associated vasculitis: prediction of outcome? *Mediators Inflamm* 2004;13:275-83.
21. Tesar V, Masek Z, *et al.* Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. *Nephrol Dial Transplant* 1998;13:1662-7.
22. Kumpers P, Hellpap J, *et al.* Circulating angiopoietin-2 is a marker and potential mediator of endothelial cell detachment in ANCA-associated vasculitis with renal involvement. *Nephrol Dial Transplant* 2009;24:1845-50.
23. Lemieux C, Maliba R, *et al.* Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. *Blood* 2005;105:1523-30.
24. Bauer S, Abdgawad M, *et al.* Proteinase 3 and CD177 are expressed on the plasma membrane of the same subset of neutrophils. *J Leukoc Biol* 2007;81:458-64.
25. Rose JJ, Foley JF, *et al.* On the mechanism and significance of ligand-induced internalization of human neutrophil chemokine receptors CXCR1 and CXCR2. *J Biol Chem* 2004;279:24372-86.
26. van der Veen BS, Petersen AH, *et al.* Spatiotemporal expression of chemokines and chemokine receptors in experimental anti-myeloperoxidase antibody-mediated glomerulonephritis. *Clin Exp Immunol* 2009;158:143-53.
27. Godaly G, Hang L, *et al.* Transepithelial neutrophil migration is CXCR1 dependent in vitro and is defective in IL-8 receptor knockout mice. *J Immunol* 2000;165:5287-94.
28. Mintz R, Garty BZ, *et al.* Reduced expression of chemoattractant receptors by polymorphonuclear leukocytes in Hyper IgE Syndrome patients. *Immunol Lett* 2010;130:97-106.
29. Olszyna DP, Florquin S, *et al.* CXC chemokine receptor 2 contributes to host defense in murine urinary tract infection. *J Infect Dis* 2001;184:301-7.
30. Slocombe RF, Malark J, *et al.* Importance of neutrophils in the pathogenesis of acute pneumonic pasteurellosis in calves. *Am J Vet Res* 1985;46:2253-8.
31. Svensson M, Irjala H, *et al.* Effects of epithelial and neutrophil CXCR2 on innate immunity and resistance to kidney infection. *Kidney Int* 2008;74:81-90.
32. Muller Kobold AC, Mesander G, *et al.* Are circulating neutrophils intravascularly activated in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides? *Clin Exp Immunol* 1998;114:491-9.

33. Casilli F, Bianchini A, *et al.* Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR<sub>1</sub> and CXCR<sub>2</sub>. *Biochem Pharmacol* 2005;69:385-94.
34. Cohen-Hillel E, Yron I, *et al.* Interleukin 8 and cell migration to inflammatory sites: the regulation of focal adhesion kinase under conditions of migratory desensitization. *Isr Med Assoc J* 2007;9:579-83.
35. Coelho FM, Pinho V, *et al.* The chemokine receptors CXCR<sub>1</sub>/CXCR<sub>2</sub> modulate antigen-induced arthritis by regulating adhesion of neutrophils to the synovial microvasculature. *Arthritis Rheum* 2008;58:2329-37.
36. Savage CO, Brooks CJ, *et al.* Cell adhesion molecule expression within human glomerular and kidney organ culture. *J Pathol* 1997;181:111-5.
37. Lally F, Smith E, *et al.* A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. *Arthritis Rheum* 2005;52:3460-9.
38. Hechtman DH, Cybulsky MI, *et al.* Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. *J Immunol* 1991;147:883-92.
39. Simonet WS, Hughes TM, *et al.* Long-term impaired neutrophil migration in mice overexpressing human interleukin-8. *J Clin Invest* 1994;94:1310-9.
40. Cockwell P, Brooks CJ, *et al.* Interleukin-8: A pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. *Kidney Int* 1999;55:852-63.
41. Mayet W, Schwarting A, *et al.* Anti-PR-3 antibodies induce endothelial IL-8 release. *Eur J Clin Invest* 1999;29:973-9.
42. Strieter RM, Kunkel SL, *et al.* Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. *Science* 1989;243:1467-9.
43. Abdulahad WH, Stegeman CA, *et al.* Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. *Arthritis Rheum* 2008;58:2196-205.
44. Khandaker MH, Mitchell G, *et al.* Metalloproteinases are involved in lipopolysaccharide- and tumor necrosis factor-alpha-mediated regulation of CXCR<sub>1</sub> and CXCR<sub>2</sub> chemokine receptor expression. *Blood* 1999;93:2173-85.
45. Chan AT, Flossmann O, *et al.* The role of biologic therapies in the management of systemic vasculitis. *Autoimmun Rev* 2006;5:273-8.
46. Huugen D, Xiao H, *et al.* Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. *Am J Pathol* 2005;167:47-58.
47. Noronha IL, Kruger C, *et al.* In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. *Kidney Int* 1993;43:682-92.



